US-based Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has announced a new supply agreement with Taiwan for 20 million doses of Moderna’s COVID-19 vaccine and its updated variant booster vaccine candidate, if authorized, to begin delivery in 2022 and an additional 15 million doses in 2023.

This new supply agreement is in addition to the prior agreement for 5 million doses in 2021.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.